Alzheimer’s disease (AD) is the most prevalent among the aging diseases known as neurodegenerative
disorders. Drug design programs over the last two decades were mainly based on the
cholinergic, the amyloid or the tau hypothesis. However, none of the new drugs have a real impact on
the outcome of the disease. The complex nature of AD has led to new approaches for drug development
programs, the multitarget drug design hypothesis. Based on this hypothesis, the generation of multitarget
hybrid compounds from previously known active molecules has been one of the most widely used
to obtain new candidates for the future treatment of AD. Here, we summarize recent developments
based on the hybridization hypothesis to obtain a potential clinical candidate for AD.
Keywords: Alzheimer's disease, Hybrid compounds, Drug design, Multitarget drugs, Emerging targets for AD, Dual AChE
Inhibitors, Antioxidants, Nrf2-EpRE inducers.
Rights & PermissionsPrintExport